[Targeted asthma therapies: confirmations, hopes, and disappointments].
Asthma is a chronic inflammatory disease of the airways. The inflammatory process is driven by different pathways involving cytokines and other protein mediators. Patients with severe asthma are at high risk of severe exacerbations and death and have few therapeutic options available. Therefore, biological agents have been developed to help patients with refractory asthma by interfering with several compounds of the asthma inflammatory cascade. In addition to decreasing exacerbations, some of those treatments have a steroid sparing role and many beneficial effects in asthmatics.
Service de Pneumologie, CHU de Liège, Belgique.
F
F
Schleich
R
R
Louis
D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D007378:Interleukins / Q000037:antagonists & inhibitors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D018927:Anti-Asthmatic Agents; D061067:Antibodies, Monoclonal, Humanized; D007378:Interleukins; D014409:Tumor Necrosis Factor-alpha; D007073:Immunoglobulin E